title: [Surveillance of falciparum malaria susceptibility to antimalarial drugs and policy change in the Comoros].
abstract: Between May and June 2001, efficacy of chloroquine was assessed in 5 sentinel sites in the 3 Comoro islands. Among the 183 children, age range between 6 and 59 months, followed up for 14 days, clinical failure rates ranged between 31.2 and 73.1% and the total failure rate (clinical and parasitological) between 50 and 88.5%. Failures were mainly early treatment failures. The Ministry of health, during a consensus meeting decided to change the first line drug and to gather baseline information on the efficacy and the tolerance of the combination artemether-lumefantrine. Between June and September 2004, among the 164 children, age range between 6 and 59 months included, the success rate of the combination was 99.4% in the 3 sites with a follow-up of 28 days. No serious drug related adverse event was reported.
authors.affiliation: Programme national de lutte contre le paludisme, Moroni, Union des Comores.
authors.forename: R
authors.initials: R
authors.lastname: Silai
authors.forename: M
authors.initials: M
authors.lastname: Moussa
authors.forename: M
authors.initials: M
authors.lastname: Abdalli Mari
authors.forename: M
authors.initials: M
authors.lastname: Astafieva-Djaza
authors.forename: M
authors.initials: M
authors.lastname: Hafidhou
authors.forename: A
authors.initials: A
authors.lastname: Oumadi
authors.forename: M
authors.initials: M
authors.lastname: Randrianarivelojosia
authors.forename: A
authors.initials: A
authors.lastname: Said Ankili
authors.forename: B
authors.initials: B
authors.lastname: Said Ahmed
authors.forename: A H
authors.initials: AH
authors.lastname: Gayibor
authors.forename: F
authors.initials: F
authors.lastname: Ariey
authors.forename: P
authors.initials: P
authors.lastname: Ringwald
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077549:Artemether; D037621:Artemisinins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002985:Clinical Protocols; D017507:Comoros / Q000453:epidemiology; D003245:Consensus Statements as Topic; D004338:Drug Combinations; D004351:Drug Resistance; D004983:Ethanolamines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005449:Fluorenes / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005838:Genotype; D006291:Health Policy / Q000639:trends; D006801:Humans; D007223:Infant; D000078102:Lumefantrine; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology / Q000517:prevention & control; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D017410:Practice Guidelines as Topic; D011635:Public Health Administration; D012008:Recurrence; D014944:World Health Organization
chemical_list: D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D002738:Chloroquine; D000077549:Artemether; D000078102:Lumefantrine